RDUS
vs
S&P 500
RDUS
S&P 500
Over the past 12 months, RDUS has significantly outperformed S&P 500, delivering a return of +98% compared to the S&P 500's +14% growth.
Stocks Performance
RDUS vs S&P 500
Performance Gap
RDUS vs S&P 500
Performance By Year
RDUS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Radius Health Inc
Glance View
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
